Equities Analysts Offer Predictions for TARS FY2025 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at Lifesci Capital lifted their FY2025 earnings per share estimates for Tarsus Pharmaceuticals in a report issued on Wednesday, November 5th. Lifesci Capital analyst C. Jubinville now forecasts that the company will earn ($1.46) per share for the year, up from their previous forecast of ($1.54). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at $0.06 EPS.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright boosted their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research note on Monday, October 20th. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. The Goldman Sachs Group reissued a “neutral” rating and issued a $51.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Guggenheim lifted their price objective on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $69.83.

Tarsus Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ TARS opened at $68.09 on Friday. Tarsus Pharmaceuticals has a 1 year low of $38.51 and a 1 year high of $76.81. The firm’s 50-day moving average is $62.57 and its 200-day moving average is $51.09. The company has a current ratio of 4.29, a quick ratio of 5.21 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $2.87 billion, a PE ratio of -33.71 and a beta of 0.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Driehaus Capital Management LLC bought a new position in Tarsus Pharmaceuticals in the first quarter valued at approximately $36,876,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Tarsus Pharmaceuticals during the first quarter worth $26,199,000. Norges Bank acquired a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth $19,095,000. MPM Bioimpact LLC bought a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at $13,834,000. Finally, Nuveen LLC acquired a new position in Tarsus Pharmaceuticals in the 1st quarter worth $13,589,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, Director William J. Phd Link sold 27,116 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the sale, the director owned 143,332 shares of the company’s stock, valued at $8,169,924. This trade represents a 15.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the transaction, the chief executive officer owned 812,106 shares in the company, valued at $44,966,309.22. This trade represents a 0.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 39,116 shares of company stock worth $2,177,832 in the last ninety days. 8.97% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.